The local medical landscape is abuzz with the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing significant results in scientific trials for addressing obesity. This medication https://sound-social.com/story12112178/the-new-retatrutide-australia-a-emerging-prospect-for-obesity-treatment